Owing to constant developments and challenges in the life sciences industry, stakeholders must continue to be adaptable, innovative, and competitive to thrive. Industry leaders must reconsider their strategic positions annually by understanding the main forces behind the transformation, including potential, challenges, and drivers.
This analysis explores the strategic imperatives shaping and transforming the life sciences industry.
They are as follows:
SaaS evolution provides adaptive intelligence for laboratories
CDMOs augment competencies in new modalities, and digital transformation delivers end-to-end partnerships
Expanding direct-to-consumer (DTC) genetic testing beyond ancestry testing to multi-pathogenic STIs
Uncertainty about trade wars disrupts pharmaceutical supply chains
Decentralized clinical trials (DCTs) boost efficiency for CGTs and rare disorders
Next-generation sequencing (NGS) and liquid biopsy revolutionize oncology diagnostics
Failed clinical trials and shifting market conditions setback biotech innovation
ESG initiatives climb to the top of CEOs' strategic priorities
Real-world insight (RWI) emerges as a strategic compass point to reimagine commercial strategies
CRISPR technology advances biologics R&D
- Strategic Imperatives
- Why is it Increasingly Difficult to Grow?
- The Strategic Imperative 8™
- Top Transformations Impacting the Growth of the Life Sciences Industry
- Key Industry Trends and Challenges
- Top 10 Transformations Impacting Growth in the Life Sciences Industry, 2025
- Transformation 1: SaaS Evolution Provides Adaptive Intelligence for Laboratories
- Transformation 2: CDMOs Augment Competencies in New Modalities, and Digital Transformation Delivers End-to-End Partnerships
- Transformation 3: Expanding Direct-to-Consumer (DTC) Genetic Testing Beyond Ancestry Testing to Multi-pathogenic STIs
- Transformation 4: Uncertainty About Trade Wars Disrupts Pharmaceutical Supply Chains
- Transformation 5: Decentralized Clinical Trials (DCTs) Boosting Efficiency for CGTs and Rare Disorders
- Transformation 6: Next-generation Sequencing (NGS) and Liquid Biopsy Revolutionize Oncology Diagnostics
- Transformation 7: Failed Clinical Trials and Shifting Market Conditions Setback Biotech Innovation
- Transformation 8: ESG Initiatives Climb to the Top of CEOs' Strategic Priorities
- Transformation 9: Real-world Insight (RWI) Emerges as a Strategic Compass Point to Reimagine Commercial Strategies
- Transformation 10: CRISPR Technology Advances Biologics R&D
- Frost & Sullivan Analytics Perspectives
- Next Steps
- Benefits and Impacts of Growth Opportunities
- Next Steps
- Legal Disclaimer
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook